Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Simcere Pharma Given OK to Start China Trial of Cancer Drug

publication date: Nov 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma was given SFDA approval to begin China clinical trials of BD0801, an anti-angiogenesis drug that will be tested as a treatment for cancer. The IND for the molecule was filed in March 2011, 19 months ago. Simcere partners the drug with Apexigen, a California company that developed a rabbit-based monoclonal antibody platform. Simcere owns China rights to BD0801, which will be the first of Apexigen’s molecules to start human trials. More details....

Stock Symbol: (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners